Progyny, Inc. reported $1.31B of revenue over the trailing twelve months, +5.5% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.31B (to Q2 2026). Net income: $79M, trailing twelve months to Q2 2026. Free cash flow: $178M, trailing twelve months to Q2 2026. Operating margin: 8.5%, trailing twelve months to Q2 2026.

PGNYProgyny, Inc.

Healthcare

$27.94+29% 1Y

$27.94

$16.3052 weeks$32.37

PGNY as reported

Progyny, Inc. reported $1.31B of revenue over the trailing twelve months, +5.5% on the year before. 10 reported series are charted on this page, each one as filed.

$1.31B

Revenue, trailing twelve months · to Q2 2026 · +5.5% against the twelve months before

Net income: $79M
Net income · +48% year on year · trailing twelve months to Q2 2026
Free cash flow: $178M
Free cash flow · −6.2% year on year · trailing twelve months to Q2 2026
Operating margin: 8.5%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PGNY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.31B	+5.5%	Q2 2026
Net income	$79M	+48%	Q2 2026
EPS	$0.92	+56%	Q2 2026
Gross margin	25%	n/a	Q2 2026
Operating margin	8.5%	n/a	Q2 2026
Net margin	5.9%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	8.9%	n/a	Q2 2026
Free cash flow	$178M	−6.2%	Q2 2026
P/E	30.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.